Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free, anticoagulant activity



Hobson, James J ORCID: 0000-0003-2551-1774, Rannard, Steve P ORCID: 0000-0002-6946-1097, Owen, Andrew ORCID: 0000-0002-9819-7651 and Liptrott, Neill J ORCID: 0000-0002-5980-8966
(2020) Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free, anticoagulant activity. Nanomedicine, 15 (14). pp. 1361-1374.

[img] Text
NE Immune Manuscript Final_R1.docx - Author Accepted Manuscript

Download (475kB)

Abstract

<jats:p> Aim: A preclinical safety assessment of a novel nanoemulsion drug-delivery system, initially developed to improve the posology of efavirenz (EFV), was conducted with a specific focus on possible immunological and hematological complications. Materials &amp; methods: Assessment of common acute toxicities, such as complement activation and cytokine secretion, was performed using validated assays known to have good correlation with in vivo end points. Results &amp; conclusion: Compared with a standard aqueous solution of EFV, the EFV nanoemulsion showed no significant effect on immune cell function or phenotype. Prolongation of activated partial thromboplastin time was observed for EFV-loaded nanoemulsions (88% at 4 μg/ml) as well as unloaded nanoemulsions (52%) highlighting the potential for drug-free anticoagulant activity and warranting further investigation of the mechanism and utility of these materials. </jats:p>

Item Type: Article
Uncontrolled Keywords: HIV, immunotoxicity, nanoemulsion, nanomedicine, preclinical, safety
Depositing User: Symplectic Admin
Date Deposited: 05 Jun 2020 08:04
Last Modified: 18 Jan 2023 23:50
DOI: 10.2217/nnm-2019-0447
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3089477